Showing 1 - 7 results of 7 for search 'Christopher W Pohlmeyer', query time: 0.03s Refine Results
  1. 1
    Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality.

    Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality. by Sarah B Laskey, Christopher W Pohlmeyer, Katherine M Bruner, Robert F Siliciano

    Published 2016-08-01
    Get full text
    Article
  2. 2
    The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication

    The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication by Victoria E. Walker-Sperling, Christopher W. Pohlmeyer, Patrick M. Tarwater, Joel N. Blankson

    Published 2016-06-01
    Get full text
    Article
  3. 3
    A CD3/CD28 microbead-based HIV-1 viral outgrowth assay

    A CD3/CD28 microbead-based HIV-1 viral outgrowth assay by Yury V. Kuzmichev, Rebecca T. Veenhuis, Christopher W. Pohlmeyer, Caroline C. Garliss, Victoria E.K. Walker-Sperling, Joel N. Blankson

    Published 2017-04-01
    Get full text
    Article
  4. 4
    Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller

    Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller by Victoria E. Walker-Sperling, Christopher W. Pohlmeyer, Rebecca T. Veenhuis, Megan May, Krystle A. Luna, Allison R. Kirkpatrick, Oliver Laeyendecker, Andrea L. Cox, Mary Carrington, Justin R. Bailey, Roberto C. Arduino, Joel N. Blankson

    Published 2017-02-01
    Get full text
    Article
  5. 5
    Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

    Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis by Christopher W. Pohlmeyer, Ching Shang, Pei Han, Zhi-Hua Cui, Randall M. Jones, Astrid S. Clarke, Bernard P. Murray, David A. Lopez, David W. Newstrom, M. David Inzunza, Franziska G. Matzkies, Kevin S. Currie, Julie A. Di Paolo

    Published 2021-03-01
    Get full text
    Article
  6. 6
    Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses.

    Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses. by Christopher W Pohlmeyer, Sarah B Laskey, Sarah E Beck, Daniel C Xu, Adam A Capoferri, Caroline C Garliss, Megan E May, Alison Livingston, Walt Lichmira, Richard D Moore, M Sue Leffell, Nicholas J Butler, Jennifer E Thorne, John A Flynn, Robert F Siliciano, Joel N Blankson

    Published 2018-01-01
    Get full text
    Article
  7. 7
    HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

    HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. by Timothy J Henrich, Hiroyu Hatano, Oliver Bacon, Louise E Hogan, Rachel Rutishauser, Alison Hill, Mary F Kearney, Elizabeth M Anderson, Susan P Buchbinder, Stephanie E Cohen, Mohamed Abdel-Mohsen, Christopher W Pohlmeyer, Remi Fromentin, Rebecca Hoh, Albert Y Liu, Joseph M McCune, Jonathan Spindler, Kelly Metcalf-Pate, Kristen S Hobbs, Cassandra Thanh, Erica A Gibson, Daniel R Kuritzkes, Robert F Siliciano, Richard W Price, Douglas D Richman, Nicolas Chomont, Janet D Siliciano, John W Mellors, Steven A Yukl, Joel N Blankson, Teri Liegler, Steven G Deeks

    Published 2017-11-01
    Get full text
    Article

Search Tools: